# Notice of Ref renc s Cited

Application/Control No. 09/544,910

Applicant(s)/Patent Under Reexamination HUANG ET AL.

Examiner

Stephen L. Rawlings, Ph.D.

Art Unit 1642

Page 1 of 5

### U.S. PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Name	Classification
	Α	US-			
	В	US-			
	C	US-			
	D	US-			
	Е	US-			
	F	US-			
,	G	US-			
	Н	US-			
	1	US-			
	J	US-			
	к	US-			
	L	US-			
	М	US-			

### FOREIGN PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Country	Name	Classification
	N					
	0					
	Р					
	Q					
	R					
	S					
	Т					

#### **NON-PATENT DOCUMENTS**

*		Include as applicable: Author, Title Date, Publisher, Edition or Volume, Pertinent Pages)
	U	Wyne, KL, et al, 1989, Rat granulosa apolipoprotein E secretion: regulation by cell cholesterol, Journal of Biological Chemistry, Vol. 264, No. 28, pp. 16530-16536.
	v	Laffitte, BA, et al, 2001, LXRs control lipid-inducible expression of the apolipoprotein E gene in macrophages and adipocytes, Proceedings of the National Academy of Sciences USA, Vol. 98, No. 2, pp. 507-512.
	w	Clavey, V, et al, 1999, Cell culture conditions determine apolipoprotein CIII secretion and regulation by fibrates in human hepatoma HepG2 cells, Cellular Physiology and Biochemistry, Vol. 9, No. 3, pp. 139-149.
	х	Ishigami, M, et al, 1998, Apolipoprotein E inhibits platelet-derived growth factor-induced vascular smooth muscle cell migration and proliferation by suppressing [], Journal of Biological Chemistry, Vol. 273, No. 32, pp. 20156-20161.

\*A copy of this reference is not being furnished with this Office action. (See MPEP § 707.05(a).)

Dates in MM-YYYY format are publication dates. Classifications may be US or foreign.

U.S. Patent and Trademark Office PTO-892 (Rev. 01-2001)

fRa 5/3/02

**Notice of References Cited** 

Part of Paper No. 18

# Notice of References Cited

Applicant(s)/Patent Under Application/Control No. Reexamination 09/544,910 HUANG ET AL. Art Unit

Examiner

Stephen L. Rawlings, Ph.D. 1642 Page 2 of 5

# U.S. PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Name	Classification
	Α	US-			
	В	US-			,
	С	US-			
	D	US-			
	Е	US-			
	F	US-			
	G	US-			
	Н	US-			
	I	US-			
	J	US-			
	κ	US-			
	L	US-			
	M	US-			

# FOREIGN PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Country	Name	Classification
	N					
	0					
	Р					
	ø					
	R					
	S					
	Т					

# **NON-PATENT DOCUMENTS**

*		Include as applicable: Author, Title Date, Publisher, Edition or Volume, Pertinent Pages)
	U	Ogbonna, G, et al, 1993, Hormonal regulation of human apolipoprotein E gene expression in HepG2 cells, International Journal of Biochemistry, Vol. 25, No. 5, pp. 635-640.
	V	Krul, ES, et al, 1992, Secretion of apolipoprotein E by an astrocytoma cell line, Journal of Neuroscience Research, vol. 32, No. 2, pp. 227-238.
	w	Civeira, F, et al, 1999, Comparison of the hypolipidemic effect of gemfibrozil versus simvastatin in patients with type III hyperlipoproteinemia, American Heart Journal, Vol. 138, No. 1, Pt. 1, pp. 156-162.
	х	Pauciullo, P, et al, 1990, Serum lipoproteins, apolipoproteins and very low density lipoprotein subfractions during 6-month fibrate treatment in primary hypertriglyceridaemia, Journal of Internal Medicine, Vol. 228, No. 5, pp. 425-430.

\*A copy of this reference is not being furnished with this Office action. (See MPEP § 707.05(a).) Dates in MM-YYYY format are publication dates. Classifications may be US or foreign.



U.S. Patent and Trademark Office PTO-892 (Rev. 01-2001)

# **Notice of References Cited**

_		
Application/Control No.	Applicant(s)/Pater	nt Under
09/544,910	Reexamination HUANG ET AL.	
Examiner	Art Unit	
Stephen L. Rawlings, Ph.D.	1642	Page 3 of 5

### U.S. PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Name	Classification
	Α	US-			
	В	US-			
	С	US-			
	D	US-			
	Е	US-			
	F	US-			
	G	US-			
	Н	US-			
	1	US-			
	J	US-			
	К	US-			
	L	US-			
	М	US-			

### FOREIGN PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Country	Name	Classification
	N					
	0					
	Р					
	Q					
	R					
	S					
	Т					

### **NON-PATENT DOCUMENTS**

*		Include as applicable: Author, Title Date, Publisher, Edition or Volume, Pertinent Pages)
	U	Lesoon-Wood, LA, et al, 1999, Enhancement of methylcholanthrene-induced neoplastic transformation in murine C3H 10T1/2 fibroblasts by antisense phophorothioate oligodeoxyribonucleotide sequences, Cancer Letters, Vol. 147, No. 1-2, pp. 163-173.
	٧	Pierce, ML, et al, 1998, Construction of a directed hammerhead reibozyme library: towards the identification of optimal target sites for antisense-mediated gene inhibition, Nucleic Acids Research, Vol. 26, No. 22, pp. 5093-5101.
	w	Sohail, M, et al, 2000, Hybridization of antisense reagents to RNA, Current Opinions in Molecular Therapy, Vol. 2, No. 3, pp. 264-271.
	х	Dvorchik, BH, 2000, The deposition (ADME) of antisense oligonucleotides, Current Opinions in Molecular Therapy, vol. 2, No. 3, pp. 253-257.

\*A copy of this reference is not being furnished with this Office action. (See MPEP § 707.05(a).) Dates in MM-YYYY format are publication dates. Classifications may be US or foreign.

U.S. Patent and Trademark Office PTO-892 (Rev. 01-2001)

# Notice of References Cit d

Application/Control No.

O9/544,910

Examiner

Stephen L. Rawlings, Ph.D.

Applicant(s)/Patent Under
Reexamination
HUANG ET AL.

Art Unit
Page 4 of 5

# U.S. PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Name	Classification
	Α	US-			
	В	US-			
	С	US-			
	D	US-			
	Е	US-			
	F	US-			
	G	US-			
	Н	US-			
	ı	US-			
	J	US-			
	к	US-			
	L	US-			
	М	US-			

# FOREIGN PATENT DOCUMENTS

				12:011 : :::::::::::::::::::::::::::::::		
*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Country	Name	Classification
	N					
	0					
	Р					
	Q					
	R					
	S					
	Т					

#### NON-PATENT DOCUMENTS

*		Include as applicable: Author, Title Date, Publisher, Edition or Volume, Pertinent Pages)					
	U	Lane, DM, et al, 1995, Changes in plasma lipid and apolipoprotein levels between heparin-induced extracorporeal low-density lipoprotein precipitation (HELP) treatments, American Journal of Cardiology, Vol. 75, No. 16, pp. 1124-1129.					
	٧	Kaiske, BL, et al, 1990, The effects of lovastatin in hyperlipidemic patients with the nephrotic syndrome, American Journal of Kidney Diseases, Vol. 15, No. 1, pp. 8-15.					
	w	Bremer, J, 2001, The biochemistry of hypo- and hyperlipidemic fatty acid derivatives: metabolism and metabolic effects, Progress in Lipid Research, Vol. 40, No. 4, pp. 231-268.					
	х	Neve, BP, et al, 2000, Role of peroxisome proliferator-activated receptors (PPAR) in atherosclerosis, Biochemical Pharmacology, Vol. 60, No. 8, pp. 1245-1250.					

\*A copy of this reference is not being furnished with this Office action. (See MPEP § 707.05(a).)

Dates in MM-YYYY format are publication dates. Classifications may be US or foreign.

SR 5/3/02

# Notic of R ferences Cited

Application/Control No.

O9/544,910

Applicant(s)/Patent Under Reexamination HUANG ET AL.

Examiner

Stephen L. Rawlings, Ph.D.

Applicant(s)/Patent Under Reexamination HUANG ET AL.

Page 5 of 5

### **U.S. PATENT DOCUMENTS**

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Name	Classification
	Α	US-			
	В	US-			
	С	US-			
	D	US-			
	E	US-			
	F	US-			
	G	US-			
	Н	US-			
	1	US-			
	J	US-			
	K	US-			
	L	US-			
	М	US-			

# FOREIGN PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Country	Name	Classification
	N					
	0					
	Р					
	Q					
	R					
	S					
	Т					

#### NON-PATENT DOCUMENTS

*	r	NON-FATENT DOCUMENTS	_
	ļ	Include as applicable: Author, Title Date, Publisher, Edition or Volume, Pertinent Pages)	
	U	Pineda Torra, I, et al, 1999, Peroxisome proliferator-activated receptor alpha in metabolic disease, inflammation, atherosclerosis and aging, Current Opinions in Lipidology, Vol. 10, No. 2, pp. 151-159.	
	V	Garg, A, Lipid-lowering therapy and macrovascular disease in diabetes mellitus, Diabetes, Vol. 41, suppl. 2, pp. 111-115.	
	w	Colwell, JA, Multifactorial aspects of the treatment of the type II diabetic patient, Metabolism: Clinical and Experimental, Vol. 46, No. 12, Suppl. 1, pp. 1-4.	
	x	Petegnief, V, et al, 2001, Neuronal injury-induced expression and release of apolipoprotein E in mixed neuron/glia co-cultures: nuclear factor kappaB inhibitors reduce basal and lesion-induced secretion of apoE, Neuroscience, Vol. 104, No. 1, pp. 223-234.	

\*A copy of this reference is not being furnished with this Office action. (See MPEP § 707.05(a).) Dates in MM-YYYY format are publication dates. Classifications may be US or foreign.

5/3/02